scholarly journals Mathematical models in cardiology: From formulas to real clinical practice

2020 ◽  
Vol 35 (4) ◽  
pp. 39-48
Author(s):  
V. A. Kuznetsov ◽  
L. I. Gapon ◽  
L. M. Malishevskii ◽  
D. S. Lobuntsov ◽  
E. A. Dziabenko ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Cardiovascular Diseases ◽  
Mathematical Models ◽  
Mobile Application ◽  
Real Life ◽  
Medical Data ◽  
Research Center ◽  
Programming Environment ◽  
Mathematical Formulas ◽  
Real Clinical Practice

Aim. To develop and implement into clinical practice six calculators of risk for various cardiovascular diseases in the form of mobile application for iOS/Android and module for the 1C: Medicine software.Material and Methods. At the premises of Tyumen Cardiology Research Center (TCRC) of Tomsk NRMC, we developed the mobile application for iOS/Android and module for the 1C: Medicine software based on six mathematical models that were invented and patented in our center earlier.Results and Discussion. The use of mobile application improved the convenience of working with the mathematical formulas and reduces the time for obtaining results of calculations. Implementation of 1C as a programming environment allowed to perform automatic filling out the calculator fields with medical data from individual patients, which significantly simplified and accelerated the rate of work with mathematical models.Conclusion. The developed mobile application and external processing for 1C allowed to implement research products of TCRC in the form of mathematical formulas into real-life clinical practice. These developments contributed to speeding up the process for acquisition of results and partial automatization of filling out the form fields.

scholarly journals Rational pharmacotherapy in real clinical practice through the prism of multimorbidity and drug safety

2020 ◽  
Vol 1 (2) ◽  
pp. 29-39
Author(s):  
Dmitry I. Trukhan ◽  
Keyword(s):  
Clinical Practice ◽  
Cardiovascular Diseases ◽  
Drug Safety ◽  
Adult Population ◽  
Premature Death ◽  
Review Article ◽  
Rational Pharmacotherapy ◽  
Real Clinical Practice

Currently, multimorbidity/comorbidity and drug safety are important components of rational pharmacotherapy in real clinical practice. Cardiovascular diseases occupy a leading place in the structure of non-infectious pathology of the adult population, being the main cause of early disability and premature death. In a review article, using clinical examples, the issues of rational pharmacotherapy in patients with cardiovascular diseases and concomitant comorbid/multimorbid pathology are considered.

scholarly journals Usage of glucometer with mobile application in real clinical practice

2020 ◽  
pp. 120-125
Author(s):  
A. V. Vitebskaya
Keyword(s):  
Diabetes Mellitus ◽  
Clinical Practice ◽  
Glycemic Control ◽  
Mobile Application ◽  
Insulin Dose ◽  
Diabetes Mellitus Type 1 ◽  
Diabetes Mellitus Type ◽  
Dose Titration ◽  
Real Clinical Practice

Introduction. Glycemic control in patients with diabetes mellitus type 1 (DM1) can be held using glucometer with mobile application, continuous glucose monitoring (CGM), and intermediately scanned CGM (isCGM). isCGM do not need calibration with glucometer as CGM, but its usage in children and adolescents is recommended only together with glucometer.Aim: to study characteristics of glucometer usage in real clinical practice in a patient which utilizes glucometer with mobile application and is CGM simultaneously.Materials and methods. A 17-year-old girl with diabetes mellitus type 1 was advised to use isCGM together with glucometer Contour Plus One (ISO 15197:2013) and mobile application Contour Diabetes.Results. The first three months, while insulin dose titration and education, the patient used glucometer 1–9 times a day (3.0 (2.0; 4.0)), filled in diary. These led to decrease of glycaemia (10.7 (5.5; 14.7) – 7.8 (5.2; 9.5) mmol/L) and variability (56–45%), increase of percent of measurements within range (38–57%), according to glucometer; decrease of mean glycaemia (11.8–8.5 mmol/L) and increase of time in range (TIR) (14–59%), according to isCGM. The next three months, while diabetes mellitus type 1 compensation, according to glucometer (glycaemia 6.9 (4.9; 9.7) mmol/L, variability 48%, percent of measurements within range 71%) and isCGM (mean glycaemia mean glycaemia 7.3 mmol/L, TIR 67%), the patient stopped to fill in diary, decreased number of measurements by glucometer to 1.0 (1.0; 2.0) times a day. Mean month glycaemia was 5.5–9.8% lower according to glucometer than isCGM. The patient used glucometer in cases with relatively high risk of hypoglycemia more often.Conclusion. Usage of glucometer with mobile application can increase adherence to treatment. If glucometer and isCGM used simultaneously the patients measure glycaemia with glucometer in cases of decompensated diabetes mellitus type 1 and while insulin titration more often. Mean month glycaemia according to glucometer, if used every day, corresponds with isCGM data. We must discuss with patients circumstances when they use glucometer because this can influence glycemic control indicators in mobile application reports.

scholarly journals Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study

Medicina ◽  
2021 ◽  
Vol 57 (9) ◽  
pp. 900
Author(s):  
Maria Livia Del Giudice ◽  
Alessandro Gozzetti ◽  
Elisabetta Antonioli ◽  
Enrico Orciuolo ◽  
Francesco Ghio ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Practice ◽  
Low Dose ◽  
Life Experience ◽  
Real Life ◽  
The Third ◽  
Line Therapy ◽  
Third Line ◽  
Line Of Therapy ◽  
Real Clinical Practice

Background and Objectives: The treatment of Myeloma after the second relapse is still challenging. The aim of the study was to investigate the outcomes of the POM-DEX regimen in real clinical practice. Materials and Methods: We retrospectively and prospectively analyzed 121 patients with MM treated with POM-DEX in three Italian sites in Tuscany. We assessed the efficacy based on IMWG Uniform Response Criteria in 106 patients who had received at least two courses of the POM-DEX regimen. The median time from diagnosis to use of POM-DEX was 65 months. POM-DEX median use was in the fourth-line therapy. 63.6% were exposed to lenalidomide or thalidomide, 40.5% to bortezomib or carfilzomib or ixazomib, 5.8% to mAbs in the immediately preceding line of therapy. Results: ORR was 43.4%. Median PFS and OS were 8.5 and 14 months. Eighty-nine patients received more than two courses: their median PFS and OS were 11 and 16 months. When used as the third line of therapy, median PFS and OS were 9 and 20 months and, when patients received POM-DEX for more than two courses, median PFS and OS were 14.5 and 22.5 months. Conclusions: POM-DEX is effective in RRMM, regardless of the latest exposure to IMiDs, PIs, and mAbs in the previous line of therapy.

In real clinical practice osteoporosis drugs are taken for a very short period: analysis of persistence in the campania region

2013 ◽  
Author(s):  
Giovanni Iolascon ◽  
Annarita Capaldo ◽  
Valentina Orlando ◽  
Enrica Menditto ◽  
Francesca Gimigliano
Keyword(s):  
Clinical Practice ◽  
Campania Region ◽  
Period Analysis ◽  
Short Period ◽  
Real Clinical Practice

PCSK9 inhibitors as an add on for the treatment of dislipemia in real clinical practice

2018 ◽  
Author(s):  
Carmen Hernandez Garcia ◽  
Cristina Maria Diaz Perdigones ◽  
Miguel Damas Fuentes ◽  
Clara Estaun Martinez ◽  
Andrea Sanchez Ramos ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Pcsk9 Inhibitors ◽  
Real Clinical Practice

Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery

2020 ◽  
Author(s):  
Lungwani Muungo
Keyword(s):  
Economic Growth ◽  
Developing Countries ◽  
Clinical Practice ◽  
Cardiovascular Diseases ◽  
Secondary Prevention ◽  
Health Authorities ◽  
Overwhelming Evidence ◽  
Core Components ◽  
Interventional Therapies ◽  
Limited Period

Despite major improvements in diagnostics and interventional therapies, cardiovascular diseases remain a major healthcare and socio-economic burden both in western and developing countries, in which this burden is increasing in closecorrelation to economic growth. Health authorities and the general population have started to recognize that the fightagainst these diseases can only be won if their burden is faced by increasing our investment on interventions in lifestylechanges and prevention. There is an overwhelming evidence of the efficacy of secondary prevention initiatives includingcardiac rehabilitation in terms of reduction in morbidity and mortality. However, secondary prevention is still too poorlyimplemented in clinical practice, often only on selected populations and over a limited period of time. The developmentof systematic and full comprehensive preventive programmes is warranted, integrated in the organization ofnational health systems. Furthermore, systematic monitoring of the process of delivery and outcomes is a necessity.

Sign in / Sign up

Export Citation Format

Share Document